Eli Lilly and Boehringer Ingelheim have changed the terms of their diabetes alliance to focus their energies on developing their big-selling Jardiance pill.
New research by The Worldcom Public Relations Group has ranked pharmaceutical companies according to their usage of digital channels – with Bayer, Pfizer and Boehringer Ingelheim coming out
Bayer and Janssen’s novel oral anticoagulant (NOAC) Xarelto has a new string to its bow after the FDA approved it to prevent blood clots in acutely ill medical patients.
Boehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, striking a multi-year oncology research deal with the University of Tex